Navigation Links
Omeros Submits New Drug Application to U.S. FDA for OMS302
Date:8/1/2013

ators and a major milestone for the company, our employees and our shareholders," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "We are preparing for a successful market launch of OMS302 and look forward to completing the transition from a development-stage to a commercial company. We expect that OMS302 will generate revenues that continue to drive our pipeline, yielding a long line of Omeros products to improve the lives of patients."

About Omeros' OMS302 Program
OMS302 is Omeros' product being developed for use during intraocular lens replacement (ILR), including cataract surgery and refractive lens exchange. OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent phenylephrine and the anti-inflammatory agent ketorolac. Omeros recently submitted a New Drug Application to the U.S. Food and Drug Administration and plans to submit a Marketing Authorization Application to the European Medicines Agency later this quarter.

ILR involves replacement of the original lens of the eye with an artificial intraocular lens. These procedures are typically performed to replace a lens opacified by a cataract or to correct a refractive error of the lens (i.e., refractive lens exchange). OMS302 is added to standard irrigation solution used in ILR and delivered within the eye to maintain intraoperative mydriasis (pupil dilation), to reduce surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous syste
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept 23, 2014  Vesselon, Inc. today ... Board of Directors, effective September 15, 2014. Dr. Raths, ... as its placement agent to market a private preferred ... and early stroke treatment. "Jurgen,s deep experience ... be a great asset to Vesselon as we develop ...
(Date:9/23/2014)... DALLAS , September 23, 2014 ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible ... Cardiovascular, Cancer, Ophthalmology, Orthopedics) - Global Forecasts to ... Market over the forecast period of 2014 to ... Billion by 2019, at CAGR of 9.6% from ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
Breaking Medicine Technology:Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 41st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4
... Korea , May 10 CrystalGenomics, Inc., a novel ... Ascending Dose) study for its novel antibiotic candidate, CG400549, has been ... , , ... targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme ...
... May 10 Par Pharmaceutical Companies, Inc. (NYSE: ... Generics Limited and Glenmark Generics Inc., USA , has ... that resolves patent litigation related to Glenmark,s challenge to Merck,s ... involving a challenge by Glenmark which sought to launch a ...
Cached Medicine Technology:CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- A test used ... geographic regions where certain lung infections are more common, a ... lung cancer is through the use of what,s known as ... imaging called FDG-PET is used, according to the study authors. ... do parts of the lungs that don,t have ...
(Date:9/23/2014)... with its advances promises of individualized genetic information ... Genetic tests are already guiding treatments of ... virus (HPC), and emerging research is showing genetic ... individual,s susceptibility to addiction to a substance, and ... appear to be many benefits inherent in the ...
(Date:9/23/2014)... Washington, DC (PRWEB) September 23, 2014 ... affordable care? The National Quality Forum (NQF) ... sheet ( http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=77687 ), and an infographic ( ... the rising cost of healthcare, how patients define ... for consumers to get the best possible healthcare ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 What: ... Manhattan’s Upper West Side that embodies the inclusion ... Eden: Christians, Scripture and the Ecological Crisis, a ... B. Rhodes Professor Emerita of Old Testament at ... for ancient wisdom that lends insight into current ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2
... revealed that women do not put on weight as a ... center said that the belief weight is gained as a ... such beliefs// are not based on facts. ... over the past few years that examined the effects of ...
... predisposed where smoking is concerned, according to a new research. ... habit. A gene which is called CYP2A6 serves to regulate ... for smoking addiction. ,People carry different forms ... particular parts of the world, and the Asiatic people show ...
... in the functioning of the heart with the progress of age ... according to a study which the Journal of the American College ... goes to show that primary aging can // be delayed by ... ,This fact has already been proved in the ...
... A DNA study conducted at the burial pits of ancient ... large-scale devastation to the city. The Golden Age of Athens ... this // epidemic, which is said to have wiped out ... epidemic was in Ethiopia, between 430-426 BC, which later spread ...
... dish ‘Haggis’ had an increased fat diet which the officials ... are now facing a high risk of getting obese and ... Haggis not more than once in a week. ... liver and heart of sheep which is mixed with oatmeal ...
... herbs along with conventional medical treatment for severe acute respiratory ... life// of such victims, according to latest reports. It may ... margin. ,The researchers of the present study ... of 654 SARS patients, treated with both allopathic and Chinese ...
Cached Medicine News: